New hope for drug-resistant prostate cancer: targeted radiation vs. standard therapy
NCT ID NCT05658003
First seen Apr 04, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study tests a radioactive drug (Lu-PSMA-617) against a switch to another hormone therapy in Chinese men with advanced prostate cancer that has spread and stopped responding to treatment. The goal is to see if the radioactive drug can delay cancer growth better than changing hormone pills. About 63 men who have not had chemotherapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210006, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210029, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110011, China
-
Novartis Investigative Site
Xian, Shanxi, 710032, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310003, China
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Guangzhou, 510060, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Tianjin, 300308, China
Conditions
Explore the condition pages connected to this study.